Management of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim
|
|
- Gerald Oliver
- 6 years ago
- Views:
Transcription
1 a holistic view - Prof. Dr. Martin Borggrefe Mannheim
2 Patients with atrial fibrillation (millions) Management of atrial fibrillation Expected prevalence of apparent AF 5,1 5,1 5,9 5,6 6,7 6,1 2,08 2,26 2,44 2,66 7,7 6,8 2,94 8,9 7,5 3,33 10,2 8,4 3,8 11,7 9,4 4,34 13,1 10,3 4,78 14,3 11,1 5,16 15,2 15,9 12,1 11,7 Mayo Clinic data (assuming no further increase in the AF incidence) 1,2 5,42 5, Year 1. Miyasaka Y et al. Circulation 114: (2006) 2. Savelieva I, Camm J. Clin Cardiol 31:55 62 (2008) 3. Go AS et al. JAMA 285: (2001) Mayo Clinic data (assuming a continued increase in the AF incidence) 1,2 ATRIA study data 2,3
3 Burden of disease : AF The Framingham Heart Study mortality curves for subjects 55 to 74 years of age (n=159) (n=133) (n=318) (n=266) Benjamin et al, Circulation 1998;98:
4 Death in AF Annual death rates 1.5-4% in controlled trials Death rate is highest in the 1st year after diagnosis No individual treatment of AF has been shown to reduce mortality - Anticoagulation improves survival in meta analyses - Successful rhythm control (sinus rhythm) is associated with better survival - Rhythm control therapy per se does not affect survival Death may be - due to AF, - a side effect of therapy, bleeds proarrhythmia periprocedural complications, - unrelated to AF Benjamin et al. Circulation 1998: Corley et al. Circulation 2004;109: Lip, Edwards, Thromb Res. 2006; 118:
5 15% Aetiology of ischemic stroke Artery occlusion % atherothrombotic % cardioembolic 15-20% lacunar 5-10 % infrequent 25 % cryptogenic
6 Stroke severity in AF (Framingham) Lin et al, Stroke 1996; 27:
7 Stroke risk in paroxysmal / sustained AF ACTIVE W subanalysis, 526 centers, 15 countries 6706 patients, 3371 on OAC (warfarin), 3335 clopidogrel + aspirin (warfarin better) Cumulative hazard rates of stroke and non-central nervous systemic embolisms Hohnloser et al. J Am Coll Cardiol 50: (2007)
8 predicted mean of cognitive performance (z-score, 95% CI) Strokes in AF - the tip of the iceberg? 20% of all strokes severe strokes Reduced cognitive performance in AF patients 0,50 0,25 0,00-0,25-0,50-0,75 Visuo-spatial abilities (NS) Working memory (NS) Executive functions (NS) Cognitive domains Learning and memory (p=0.01) Knecht et al. Eur Heart J 2008; 29, patients with AF without stroke 563 control subjects
9 Why do we treat AF? 1. Death 2. Stroke and cerebral bleeds 3. Quality of life 4. Rhythm 5. Left ventricular function 6. Health economics 7. Additional important outcome variables: cardiovascular complications, e.g. acute coronary syndrome or decompensated heart failure 2nd AFNET/EHRA consensus document. Kirchhof P, et al. Europace/EurHJ 2009 (June 17th 2009)
10 Why do we treat AF? 8. Silent stroke (including asymptomatic intracerebral bleeds) and cognitive function 9. Social functioning and disease-related quality of life 10. Progression to more sustained forms of AF 11. Left ventricular function 12. Left atrial function 2nd AFNET/EHRA consensus document. Kirchhof P, et al. Europace/EurHJ 2009 (June 17th 2009)
11 The "ECG focused" approach Rhythm control Time to first recurrence of AF Number of recurrences over time Recurrences identified by: Routine ECGs/symptomatic ECGs Prolonged monitoring: event recorders, automated recorders Rate control Ventricular rate in AF (ECG, Holter, GXT) Outcomes in AF, Oct (2)
12 Major Trials Comparing Rhythm Strategy and Rate Strategy Major trials include: AFFIRM RACE PIAF, STAF, HOT CAFE AF-CHF Major overall findings: Rhythm-control strategy was not superior to rate-control strategy in terms of morbidity/mortality Appropriate choice of therapy should be based on each patient s symptoms and disease Comprehensive management of patients with AF can involve rate control, prevention of thromboembolism, and correction of the rhythm disturbance - these strategies are not mutually exclusive 1. The AFFIRM Investigators. N Engl J Med. 2002;347: ; 2. Van Gelder IC, et al. N Engl J Med. 2002;347: ; 3. Hohnloser SH, et al. Lancet. 2000;356: ; 4. Carlsson J, et al. J Am Coll Cardiol. 2003;41: ; 5. Opolski G, et al. Chest. 2004;126: ; 6. Roy D, et al. N Engl J Med. 2008;358: ; 7. Fuster V, et al. Circulation. 2006;114:e257-e354.
13 Mortality (% patients) Event-free survival (%) AFFIRM and RACE: Main Results AFFIRM All-cause death 27% vs 26% (P = ) RACE Death, CVA/TIA, hospitalization -5.4% 90% CI(-11%, 0.4%) % Rate control Rhythm control Rate control % Rhythm control Years Years
14 What is Adequate Rate Control? Beats per minute < 110 < 110 < < 100 < 80 < Concerns Definition of heart rate control based on benefits from short term hemodynamic studies Not well studied with regards to regularity vs irregularity No standardised method of assessment 0 AFFIRM Rest Mild exercise RACE RACE 2 strict RACE 2 lenient Guidelines Proposal bpm at rest to 115 bpm during moderate exercise ACC/AHA/ESC Guidelines. Eur Heart J. 2006;27:
15 McNamara RL et al., Ann Intern Med 139: (2003) Management of atrial fibrillation Most ion channel blockers double SR rate
16 Amiodarone prevents recurrent AF better than sotalol or propafenone Roy D, et al. N Engl J Med.342: (2000) Singh BN, et al. N Engl J Med.352: (2005)
17 How can we improve AA drug therapy? Identify patients at risk for proarrhythmia Shortening of therapy duration New (multi channel inhibitor) drugs
18 How can we improve AA drug therapy? Identify patients at risk for proarrhythmia Shortening of therapy duration New (multi channel inhibitor) drugs
19 abnormal QT prolongation (K + blocker) abnormal QRS prolongation (Na + blocker) > 0,06s QT-prolongation or QT > 0,5s > 25% QRS increase during initiation of antiarrhythmic drug therapy are clear indicators for a risk of proarrhythmia modified from Kirchhof P, et al. Heart.92: (2006)
20 How can we improve AA drug therapy? Identify patients at risk for proarrhythmia Shortening of therapy duration New (multi channel inhibitor) drugs
21 pill in the pocket : Convert AF at home 210 patients enrolled - flecainide effective in hospital 165 patients with recurrences (79%) 569 / 618 treated episodes (92%) 534 / 569 conversion to SR (94%) - outpatient single dose 300 / 200 mg flecainide 600 / 450 mg propafenone Alboni et al, NEJM 351: (2004)
22 Comprehensive management of AF AF requires therapy of all ist causes often multimodal therapy of different factors may prevent progression of AF Adequate anticoagulation will prevent strokes and potentially cognitive decline Better treatment of concomitant conditions Hypertension, diabetes, vascular disease, structural heart disease, LV failure, smoking may prevent AF-related complications and potentially maintain SR Early, comprehensive rhythm control therapy may allow to stabilize rhythm and to prevent AF-related complications may allow to maintain SR and to prevent AF-related complications 2 nd AFNET/EHRA consensus document, Kirchhof P, et al. Eur Heart J.30: c (2009)
23 AF Increases Risk Along the Cardiovascular Continuum Remodelling Ventricular dilation MI Heart failure Atherosclerosis and LVH Risk factors (diabetes, hypertension) Atrial fibrillation 1,2 End-stage microvascular and heart disease Death 1. Benjamin EJ, et al. JAMA. 1994;271: ; 2. Krahn AD, et al. Am J Med. 1995;98: ; 3. Nakashima H, et al. Circulation. 2000;101: ; 4. Tsai CT, et al. Circulation. 2004;109:
24 Camm et al. Eur Heart 2012; 33:
25 Risk factor CHA2DS2-VASc-Score C Congestive heart failure /LV dysfunction 1 H Hypertension 1 A2 Age 75 2 D Diabetes mellitus 1 S2 Stroke / TIA / thrombo-emoblism 2 V Vascular disease 1 A Age S Sex category (i.e. female sex) 1 Maximum score 9 Score
26 Stroke risk CHA 2 DS 2 -VASC
27 Indications for oral anticoagulant Camm et al. Eur Heart J 2012; 33;
28 Clinical trials involving novel anticoagulants vs. warfarin for stroke prevention in non-valvular AF - 1 Camm et al. Eur Heart 2012; 33:
29 Clinical trials involving novel anticoagulants vs. warfarin for stroke prevention in non-valvular AF - 2 Camm et al. Eur Heart 2012; 33:
30 N Engl J Med 2011; 365:883-91
31 Cumulative Rates of the Primary End Point (Stroke or Systemic Embolism) in the Per-Protocol Population Patel et al, N Engl J Med 2011; 365:883-91
32 % pro Jahr Primary endpoint [ITT-Analysis] [Stroke or systemic embolism] % pro Jahr RE-LY (gesamt) RE-LY (CHADS 3-6) * ROCKET-AF 3 RR 0,79 (95 % KI: 0,59 1,06)** RR 0,70 (95 % KI: 0,52 0,95)*** 3 RR 0,88 (95 % KI: 0,74 1,03) p=0, ,68 RR 0,90 (95 % KI: 0,74 1,10) 2,42 2 p=0,30 + RR 0,65 (95 % KI: 0,52 0,81) 2,12 2 2,12 p<0, ,71 1,88 1,54 1 1, D110 mg D150 mg Warfarin D110 mg D150 mg Warfarin Rivaroxaban Warfarin 0 Mahaffey ; Oral presentation at AHA, 15th November 2010; Connolly et al. N Eng J Med 2009; 361: ; Connolly et al. N Eng J Med 2010; 363: ; Oldgren et al. J Am Coll Cardiol 2010; 55: A1.E2; Oldgren J. Oral presentation at ACC, Atlanta, Mar 15th 2010
33 Lancet 2014; 383:955-62
34 Meta-analysis of RE-LY, ROCKET AF, ARISTOTLE, and Engage AF-TIMI Stroke or systemic embolic events Ruff et al. Lancet 2014; 383:955-62
35 Meta-analysis of RE-LY, ROCKET AF, ARISTOTLE, and Engage AF-TIMI Secondary efficacy and safety outcomes Ruff et al. Lancet 2014; 383:955-62
36 Meta-analysis of RE-LY, ROCKET AF, ARISTOTLE, and Engage AF-TIMI Major bleeding Ruff et al. Lancet 2014; 383:955-62
37 May Jun Jul Aug Sep Oct Nov Dec Jan 11 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 12 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 13 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 14 Feb Mar Sales EUR DOACs Sales Nov 2013: Rivaroxaban 29 Mio, Dabigatran 8 Mio, Apixaban 2.4 Mio Sales DOACs ( ) RIVAROXABAN DABIGATRAN ETEXILATE APIXABAN
38 N Engl J Med 2012;366:120-9.
39 Risk of ischemic stroke or systemic embolism Healey et al. N Engl J Med 2012;366:120-9
40 Screening of AF Camm et al. Eur Heart 2012; 33:
41 Catheter Ablation and Atrial Fibrillation Peters et al. Lancet 2002; 359:
42
43
44 Ablation versus Antiarrhythmic therapy: Randomized Trials Tung et al. Circulation 2012; 126:
45 Catheter Ablation and Atrial Fibrillation AF ablation: what do we know in 2015? Catheter ablation can effectively eliminate paroxysmal AF. The most successful treatment strategy is circumferential and complete PV-isolation. The complication rate of radiofrequency catheter ablation of atrial fibrillation is 4%, ablation-associated mortality is low.
46 Circ Arrhythm Electrophysiol 2013; 6:
47 Complications of AF Ablation Major complications No. of studies % pooled complication rate (95% CI) I² statistic Acute complication rate ( ) 83.8 Type of complication Death ( ) 0.0 Atrioesophageal fistula ( ) 0.0 Pulmonary vein stenosis ( ) 79.6 Vascular complications ( ) 94.1 Arteriovenous fistula ( ) 45.5 Femoral pseudoaneurysm ( ) 41.2 Stroke/TIA ( ) 46.8 Stroke ( ) 34.3 TIA ( ) 37.9 Tamponade ( ) 68.5 Pericardial effusion ( ) 55.0 Phrenic nerve injury ( ) 70.2 Diaphragmatic paralysis ( ) 0.0 DVT/PE ( ) 0.0 Pneumothorax ( ) 0.0 Hemothorax ( ) 0.0 Gupta et al. Circ Arrhythm Electrophysiol 2013; 6: Sepsis, abscesses, or endocarditis ( ) 0.0 Valve damage ( ) 0.0 Gupta et al. Circ Arrhythm Electrophysiol 2013; 6:
48 Ablation strategy description Complications of AF Ablation Ablation strategy No. of studies % pooled complication rate (95% CI) P Value I² statistic 1 PVI alone ( ) PVA ablation/pvai ( ) Linear substrate ( ) CEAE alone ( ) CFAE as adjunct ( ) Tailored ( ) Stepwise ( ) Gupta et al. Circ Arrhythm Electrophysiol 2013; 6:
49 Electrical and structural remodelling Management of atrial fibrillation Catheter Ablation and Atrial Fibrillation Is AF ablation curative? Atrial fibrillation as progressive atrial cardiomyopathy Time
50 Electrical and structural remodelling Management of atrial fibrillation Catheter Ablation and Atrial Fibrillation When is the right time for ablation? Atrial fibrillation as progressive atrial cardiomyopathy Time
51 Circulation 2010; 122:
52 Paroxysmal Atrial Fibrillation Kaplan-Meier analysis of longterm freedom from recurrent ATas after the initial procedure (A) and after the last ablation procedure with a median of 1 (1 to 3) ablation procedure (B). Ouyang et al. Circulation 2010; 122:
53 Catheter Ablation and Atrial Fibrillation Impact of mega-trials on the future of AF ablation
What s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationDevice detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationLong-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation
Long-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation Carlo Pappone, MD, PhD, FACC EP Director, Villa Maria Hospital Group How many times AF can increase mortality DO MORTALITY REALLY
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationEHRA/EUROPACE 2011 Madrid, Spain June
EHRA/EUROPACE 2011 Madrid, Spain June 26.-29.2011 Implementing modern management in atrial fibrillation patients Proceedings from the 3rd AFNet/EHRA consensus conference EHRA Special Session Different
More informationMANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017
MANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017 1 Faculty Disclosure Faculty: Peter Leong-Sit MSc, MD, FRCPC, FHRS Associate Professor, Western University Cardiologist, London Heart
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Atrial Fibrillation Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic UC SF Division of
More informationAtrial Fibrillation Management in the ED. J Fisher May 2014"
Atrial Fibrillation Management in the ED J Fisher May 2014" A 48 yr old man presents with palpitations. He had a big night last night with old mates. ECG How will you manage him? Why important? Common
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationConflicts of Interests
Advances in the Management of Atrial Fibrillation State of the Art in 2013 Overview of AF Stroke risk and anticoagulation Rate control Antiarrhythmic Drug Therapy Catheter ablation Conclusion Hugh Calkins
More informationAtrial Fibrillation in the Elderly: Causes, Symptoms, and Treatment
Atrial Fibrillation in the Elderly: Causes, Symptoms, and Treatment Asa Oxner, MD Assistant Professor of Medicine Division of General Internal Medicine University of South Florida Co-Investigator: Geriatric
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationLong Standing Persistent AF ; CPVI is enough for it
Long Standing Persistent AF ; CPVI is enough for it Kee-Joon Choi, MD University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Boston AF Symposium 2012 In a patient undergoing AF ablation
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationIn Whom and When Should Atrial Fibrillation Ablation be Considered?
In Whom and When Should Atrial Fibrillation Ablation be Considered? Christian de Chillou, MD, PhD Department of Cardiology University Hospital Nancy, France ESC 2010 Stockholm, August 30. 2010 2 In Whom?
More informationΚατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.
Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ» Rhythm control antiarrhythmic drugs vs catheter ablation Summary
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More information3/25/2017. Program Outline. Classification of Atrial Fibrillation
Alternate Strategies to Antiarrhythmic Therapy: The Role of Ablation Jennifer El Aile, MS, AGPCNP-BC Electrophysiology Nurse Practitioner Clinical Lecturer at the University of Michigan Program Outline
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital
ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital Rate control versus Rhythm control for Atrial Fibrillation AFFIRM N Engl J Med 2002;347:1825-33
More informationFred Kusumoto Professor of Medicine
Fred Kusumoto Professor of Medicine Faculty photo will be placed here Kusumoto.Fred@mayo.edu 2015 MFMER 3543652-1 Atrial Fibrillation Presentation Subtitle Here Mayo School of Continuous Professional Development
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationAF in Andrew Staniforth. Mayo Course March 2014
AF in 2014 Andrew Staniforth Mayo Course March 2014 European Heart Journal 2010; 31: 2369 2429 www escardio.org/guidelines Q1 (Indications for anticoagulation) For stroke prevention in AF, which of the
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationCatheter ablation is not a class I indication after failed antiarrhythmic drugs
Catheter ablation is not a class I indication after failed antiarrhythmic drugs Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationModest Medtronic. Modest Boehringer Ingelheim
Adults With AF (millions) Modest Medtronic Modest Boehringer Ingelheim Changing Modalities of Care for Atrial Fibrillation Jill Repoley MSN, CRNP, CCDS, CEPS, FHRS 7 6 5 4 3 2 1 2.08 2.26 2.44 2.66 2.94
More informationAtrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD
Atrial Fibrillation and Common Supraventricular Tachycardias Sunil Kapur MD Cardiac Electrophysiology Brigham and Women s Hospital Instructor, Harvard Medical School No disclosures Cardiac Conduction:
More informationAtrial Fibrillation 2009
Atrial Fibrillation 2009 Michael Glikson, MD Director of Pacing & Electrophysiology Leviev Heart Center Sheba medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center Rhythm vs rate control
More informationFibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
More informationManagement of atrial fibrillation in diabetes
Stephen Dobbin 1 MBChB, MRCP, Cardiology SpR Miles Fisher 2 MD, FRCP, Consultant Physician Gerry McKay 2 BSc (Hons), FRCP, Consultant Physician 1 Department of Cardiology, Golden Jubilee National Hospital,
More informationDipen Shah Cardiology Service, University Hospitals, Geneva Switzerland
Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Disclosures Research Grants: Biosense Webster, St. Jude, Bard, Endosense, Biotronik Speakers Honoraria: Biosense Webster, Endosense,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationESC. Update of the ESC Guidelines on Medical Therapy. John Camm. ICM Internationales Congress Center München
ESC 2012 ICM Internationales Congress Center München Update on Consensus Statements on Management of Atrial Fibrillation European Heart Rhythm Association Update of the ESC Guidelines on Medical Therapy
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationAtrial Fibrillation: Guidelines through clinical cases and 2010 updates
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology World incidence 720, 000 new cases / year World prevalence 5.5 million
More information5/5/2010. World incidence 720, 000 new cases / year. World prevalence 5.55 million AF prevalence increasing with aging of population
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology UK World incidence 720, 000 new cases / year World prevalence 5.55
More informationAtrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice Walid Saliba, MD, FHRS Director, Atrial Fibrillation Center Director EP laboratory Heart and Vascular Institute Cleveland
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationPrimary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation
Primary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation Anne B. Curtis, MD, FACC, FHRS, FACP, FAHA Charles and Mary Bauer Professor, Chair,
More informationAtrial Fibrillation: It s More than a Rhythm
Atrial Fibrillation: It s More than a Rhythm Relax and Learn at the Farm 2013 DNP, RN, CCNS, CCRN-CMC, CHFN Cardiovascular Nursing Education Associates 1 The Quality of a Person s Life is Directly Proportional
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationAtrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
More informationDr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland
Dr Chris Ellis Consultant Cardiologist Auckland City Hospital Auckland 8:30-9:25 WS #189: Anticoagulation in AF 9:35-10:30 WS #201: Anticoagulation in AF (Repeated) Anticoagulation in Atrial Fibrillation
More informationThe 5 Most Important Things You Need to Know About Atrial Fibrillation. John D. Day, MD Director, Intermountain Heart Rhythm Specialists
The 5 Most Important Things You Need to Know About Atrial Fibrillation John D. Day, MD Director, Intermountain Heart Rhythm Specialists None Disclosures The 5 Most Important Things You Need to Know About
More informationObjectives for Technicians. Objectives for Pharmacists. Pathophysiology. Conflict of Interest. Atrial Fibrillation
Warfar IN or Warfar-OUT? And Other Updates in the Management of Atrial Fibrillation Kimberly Ackerbauer, PharmD, BCPS Clinical Pharmacy Specialist Rush University Medical Center Conflict of Interest I
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More information